{"nctId":"NCT04362813","briefTitle":"Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia","startDateStruct":{"date":"2020-04-30","type":"ACTUAL"},"conditions":["Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia"],"count":454,"armGroups":[{"label":"Canakinumab","type":"EXPERIMENTAL","interventionNames":["Drug: Canakinumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Canakinumab","otherNames":["ACZ885"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key inclusion Criteria:\n\n* Adults ≥ 18 years old (for US only: patients ≥ 12 years old, although no children ever enrolled. This was an adult trial.)\n* Body weight ≥40 kg\n* Informed consent must be obtained prior to participation in this study. For US patients 12 - \\< 18 years old; parent/guardian consent must be obtained and assent if applicable.\n* Clinically diagnosed with SARS-CoV-2 virus by PCR or by other approved diagnostic methodology\n* Hospitalized with COVID-19-induced pneumonia evidenced by chest x-ray or CT scan with pulmonary infiltrates\n* SpO2 ≤ 93% on room air or arterial oxygen partial pressure (PaO2)/ fraction of inspired oxygen (FiO2) \\< 300mmHg\n* C-reactive protein ≥20 mg/L or ferritin level ≥600 µg/L\n\nKey exclusion Criteria:\n\n* History of hypersensitivity to canakinumab or to biologic drugs\n* Intubated and on mechanical ventilation (invasive) at time of randomization\n* Treatment with immunomodulators or immunosuppressant drugs, including but not limited to tocilizumab, TNF inhibitors and anti-IL-17 agents within 5 half-lives or 30 days (whichever is longer) prior to randomization with the exception of anakinra which is excluded within 5 half-lives only. Note: Immunomodulators (topical or inhaled) for asthma and atopic dermatitis and corticosteroids (any route of administration) are permitted.\n* Suspected or known untreated active bacterial, fungal, viral, or parasitic infection with the exception of COVID-19","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants Who Survived Without Requiring Invasive Mechanical Ventilation From Day 3 to Day 29, Primary Analysis","description":"Number of responders who survived without requiring invasive mechanical ventilation from Day 3 to Day 29. An early dropout without requiring invasive mechanical ventilation is considered as a responder if discharged from hospital with 9-point ordinal scale\\<=1 or with last 9-point ordinal scale on/after Day 15 better than baseline.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"198","spread":null},{"groupId":"OG001","value":"191","spread":null}]}]}]},{"type":"SECONDARY","title":"COVID-19-related Death After Study Treatment","description":"Participants with COVID-19 related (as assessed by investigator) death up to Day 29","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratio to Baseline in the C-reactive Protein (CRP)","description":"Measurement of C Reactive Protein (mg/L), Serum Or Plasma over time. The level of C-reactive protein (CRP), which can be measured in the blood, increases when there's inflammation in the body. Lower values of ratio to baseline in the CRP indicates less inflammation. The ratio to baseline at each time point (day) for each patient is calculated as the level of a specific biomarker at the time point divided by the baseline level of the biomarker, where baseline is the last non-missing value before study treatment. The geometric mean of ratio to baseline at each time point for each treatment group is calculated by first averaging the logarithms of the ratios to baseline and then take the exponential function of the same base.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.726","spread":null},{"groupId":"OG001","value":"0.785","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.479","spread":null},{"groupId":"OG001","value":"0.649","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.255","spread":null},{"groupId":"OG001","value":"0.384","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.160","spread":null},{"groupId":"OG001","value":"0.238","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.131","spread":null},{"groupId":"OG001","value":"0.159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.099","spread":null},{"groupId":"OG001","value":"0.133","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.108","spread":null},{"groupId":"OG001","value":"0.141","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.133","spread":null},{"groupId":"OG001","value":"0.149","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.123","spread":null},{"groupId":"OG001","value":"0.289","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.123","spread":null},{"groupId":"OG001","value":"0.368","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.115","spread":null},{"groupId":"OG001","value":"0.296","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.106","spread":null},{"groupId":"OG001","value":"0.400","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.126","spread":null},{"groupId":"OG001","value":"0.368","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.175","spread":null},{"groupId":"OG001","value":"0.331","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.240","spread":null},{"groupId":"OG001","value":"0.258","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratio to Baseline in the D-dimer","description":"Clinical chemistry measurement D-Dimer (mg/L FEU), Blood in a blood sample over time\n\nD-dimer is one of the protein fragments produced when a blood clot gets dissolved in the body. The ratio to baseline at each time point (day) for each patient is calculated as the level of a specific biomarker at the time point divided by the baseline level of the biomarker, where baseline is the last non-missing value before study treatment. The geometric mean of ratio to baseline at each time point for each treatment group is calculated by first averaging the logarithms of the ratios to baseline and then take the exponential function of the same base.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.032","spread":null},{"groupId":"OG001","value":"1.028","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.992","spread":null},{"groupId":"OG001","value":"1.188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.094","spread":null},{"groupId":"OG001","value":"1.188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.038","spread":null},{"groupId":"OG001","value":"1.244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.164","spread":null},{"groupId":"OG001","value":"1.184","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.162","spread":null},{"groupId":"OG001","value":"1.115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.135","spread":null},{"groupId":"OG001","value":"1.184","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.100","spread":null},{"groupId":"OG001","value":"1.078","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.033","spread":null},{"groupId":"OG001","value":"1.384","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.520","spread":null},{"groupId":"OG001","value":"1.446","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.431","spread":null},{"groupId":"OG001","value":"1.443","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.208","spread":null},{"groupId":"OG001","value":"1.521","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.670","spread":null},{"groupId":"OG001","value":"1.808","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.785","spread":null},{"groupId":"OG001","value":"2.262","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.818","spread":null},{"groupId":"OG001","value":"2.441","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratio to Baseline in Ferritin","description":"Clinical chemistry measurement for amount of ferritin (ug/L) in Serum. The ratio to baseline at each time point (day) for each patient is calculated as the level of a specific biomarker at the time point divided by the baseline level of the biomarker, where baseline is the last non-missing value before study treatment. The geometric mean of ratio to baseline at each time point for each treatment group is calculated by first averaging the logarithms of the ratios to baseline and then take the exponential function of the same base.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.996","spread":null},{"groupId":"OG001","value":"1.014","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.921","spread":null},{"groupId":"OG001","value":"1.014","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.825","spread":null},{"groupId":"OG001","value":"0.879","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.761","spread":null},{"groupId":"OG001","value":"0.815","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.676","spread":null},{"groupId":"OG001","value":"0.764","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.618","spread":null},{"groupId":"OG001","value":"0.735","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.582","spread":null},{"groupId":"OG001","value":"0.684","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.535","spread":null},{"groupId":"OG001","value":"0.618","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.534","spread":null},{"groupId":"OG001","value":"0.641","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.545","spread":null},{"groupId":"OG001","value":"0.644","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.514","spread":null},{"groupId":"OG001","value":"0.644","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.469","spread":null},{"groupId":"OG001","value":"0.692","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.542","spread":null},{"groupId":"OG001","value":"0.745","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.490","spread":null},{"groupId":"OG001","value":"0.809","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.543","spread":null},{"groupId":"OG001","value":"0.517","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events","description":"Number of participants with treatment emergent adverse events, including changes from baseline in vital signs and laboratory results qualifying and reported as adverse events.\n\nSafety was monitored from the canakinumab or placebo dose (Day 1) up to 126 days post-dose (Day 127).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null},{"groupId":"OG001","value":"140","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":47,"n":225},"commonTop":["Hypotension","Anaemia"]}}}